(21/05/2017)vs
ΙΑΤΡΙΚΗ ΔΙΑΓΝΩΣΗ ΣΑΛΒΑΡΑ | 00 | 0 | 0 / 00% | 0 / 10% | 0 / 30% | 0 / 40% | | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | 0 |
(07/05/2017)vs
ΠΗΓΑΣΟΣ | 00 | 0 | 0 / 00% | 0 / 00% | 0 / 00% | 0 / 00% | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
(22/04/2017)vs
ΠΟΛΙΤΙΣΤΙΚΟ ΚΕΝΤΡΟ ΕΡΓΑΖΟΜΕΝΩΝ Ε.ΥΔ.ΑΠ. | 00 | 2 | 0 / 00% | 1 / 250% | 0 / 60% | 1 / 812.5% | | 0 | 0 | 1 | 1 | 0 | 3 | 0 | 1 | -2 |
(09/04/2017)vs
ΙΑΤΡΙΚΗ ΔΙΑΓΝΩΣΗ ΣΑΛΒΑΡΑ | 00 | 5 | 0 / 00% | 1 / 1100% | 1 / 333.3% | 2 / 450% | | 3 | 2 | 0 | 2 | 0 | 1 | 0 | 3 | 3 |
(02/04/2017)vs
VITEX | 00 | 5 | 0 / 00% | 1 / 333.3% | 1 / 812.5% | 2 / 1118.2% | | 1 | 3 | 2 | 5 | 2 | 1 | 0 | 1 | 3 |
(19/03/2017)vs
MINERVA MARINE | 00 | 6 | 2 / 2100% | 2 / 366.7% | 0 / 60% | 2 / 922.2% | | 1 | 0 | 2 | 2 | 0 | 2 | 0 | 2 | 1 |
(11/03/2017)vs
ΚΑΤΣΕΛΗΣ | 00 | 6 | 0 / 00% | 3 / 650% | 0 / 30% | 3 / 933.3% | | 0 | 2 | 1 | 3 | 1 | 3 | 0 | 0 | 7 |
(05/03/2017)vs
ΑΣΤΡΟΝ ΧΗΜΙΚΑ | 00 | 5 | 0 / 00% | 1 / 1100% | 1 / 616.7% | 2 / 728.6% | | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 3 |
(19/02/2017)vs
ELNAVI | 00 | 8 | 0 / 00% | 1 / 425% | 2 / 633.3% | 3 / 1030% | | 0 | 3 | 0 | 3 | 1 | 2 | 0 | 1 | 6 |
(11/02/2017)vs
ΠΗΓΑΣΟΣ | 00 | 9 | 1 / 333.3% | 4 / 757.1% | 0 / 30% | 4 / 1040% | | 0 | 1 | 1 | 2 | 2 | 2 | 1 | 0 | 8 |
(22/01/2017)vs
ΙΑΤΡΙΚΗ ΔΙΑΓΝΩΣΗ ΣΑΛΒΑΡΑ | 00 | 2 | 0 / 00% | 1 / 250% | 0 / 20% | 1 / 425% | | 0 | 2 | 1 | 3 | 1 | 1 | 0 | 0 | 4 |
(14/01/2017)vs
VITEX | 00 | 8 | 0 / 00% | 1 / 250% | 2 / 450% | 3 / 650% | | 2 | 2 | 2 | 4 | 0 | 1 | 0 | 1 | 9 |
(18/12/2016)vs
MINERVA MARINE | 18 | 0 | 0 / 20% | 0 / 20% | 0 / 60% | 0 / 80% | | 1 | 1 | 3 | 4 | 1 | 4 | 0 | 1 | -2 |
(11/12/2016)vs
ΚΑΤΣΕΛΗΣ | 00 | 11 | 0 / 00% | 1 / 250% | 3 / 650% | 4 / 850% | | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 7 |
(04/12/2016)vs
ΑΣΤΡΟΝ ΧΗΜΙΚΑ | 00 | 14 | 0 / 00% | 1 / 1100% | 4 / 580% | 5 / 683.3% | | 1 | 2 | 1 | 3 | 3 | 5 | 0 | 4 | 20 |
(27/11/2016)vs
OMS | 00 | 0 | 0 / 00% | 0 / 20% | 0 / 30% | 0 / 50% | | 0 | 1 | 2 | 3 | 0 | 0 | 0 | 0 | -2 |
(13/11/2016)vs
OMS | 00 | 0 | 0 / 00% | 0 / 30% | 0 / 50% | 0 / 80% | | 1 | 3 | 1 | 4 | 2 | 0 | 0 | 0 | -2 |
(16/10/2016)vs
OMS | 00 | 0 | 0 / 00% | 0 / 00% | 0 / 10% | 0 / 10% | | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -2 |
(09/10/2016)vs
PHARMACIA | 00 | 0 | 0 / 00% | 0 / 20% | 0 / 00% | 0 / 20% | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 |
| ΣΥΝΟΛΙΚΑ |
18 |
81 |
3 / 742.9% |
18 / 4440.9% |
14 / 7618.4% |
32 / 12026.7% |
|
13 |
26 |
18 |
44 |
14 |
27 |
1 |
16 |
59 |
| ΜΕΣΟΙ ΟΡΟΙ |
0.9 |
4.3 |
0.2 / 0.442.9% |
0.9 / 2.340.9% |
0.7 / 418.4% |
1.7 / 6.326.7% |
|
0.7 |
1.4 |
0.9 |
2.3 |
0.7 |
1.4 |
0.1 |
0.8 |
3.1 |